Assessment of RET/PTC1 and RET/PTC3 rearrangements in fine-needle aspiration biopsy specimens collected from patients with Hashimoto's thyroiditis

Thyroid Research

Volumn 4, Issue 1, 2011, Pages

  Cyniak Magierska, Anna ^a,b   Wojciechowska Durczyska, Katarzyna ^a,b   Krawczyk Rusiecka, Kinga ^a,b   Zygmunt, Arkadiusz ^a,b   Lewiski, Andrzej ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78751651323     PISSN: None     EISSN: 17566614     Source Type: Journal    
DOI: 10.1186/1756-6614-4-5     Document Type: Article

References (18)

1. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. M Grieco M Santoro MT Berlingieri RM Melillo R Donghi I Bongarzone MA Pierotti G Della Porta A Fusco G Vecchio, Cell 1990 60 557 563 10.1016/0092-8674(90)90659-3 2406025
2. RET oncogene activation in papillary thyroid carcinoma. G Tallini SL Asa, Adv Anat Pathol 2001 8 345 354 10.1097/00125480-200111000-00005 11707626
3. RET/PTC rearrangement in thyroid tumors. YE Nikiforov, Endocr Pathol 2002 13 3 16 10.1385/EP:13:1:03 12114746
4. Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. M Santoro NA Dathan MT Berlingieri I Bongarzone C Paulin M Grieco MA Pierotti G Vecchio A Fusco, Oncogene 1994 9 509 516 8290261
5. -20 years of RET/PTC in thyroid cancer: clinicopathological correlations. A Fusco M Santoro, Arq Bras Endocrinol Metabol 2007 51 731 735 17891236
6. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. Z Zhu R Ciampi MN Nikiforova M Gandhi YE Nikiforov, J Clin Endocrinol Metab 2006 91 3603 3610 10.1210/jc.2006-1006 16772343
7. High prevalence of activating RET proto-oncogene rearrangements in thyroid tumors from patients who had received external radiation. A Bounancer R Wicker B Caillou AF Cailleux A Sarasin M Schlumberger HG Suarez, Oncogene 1997 15 1263 1273 10.1038/sj.onc.1200206 9315093
8. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. J Smida K Salassidis L Hieber H Zitzelsberger AM Kellerer EP Demidchik T Negele F Spelsberg E Lengfelder M Werner M Bauchinger, Int J Cancer 1999 80 32 38 10.1002/(SICI)1097- 0215(19990105)80:1<32::AID-IJC73.0.CO;2-L 9935226
9. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. G Tallini M Santoro M Helie F Carlomagno G Salvatore G Chiappetta ML Carcangiu A Fusco, Clin Cancer Res 1998 4 287 294 9516913
10. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hürthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. G Chiappetta P Toti F Cetta A Giuliano F Pentimalli I Amendola S Lazzi M Monaco L Mazzuchelli P Tosi M Santoro A Fusco, J Clin Endocrinol Metab 2002 87 364 369 10.1210/jc.87.1.364 11788677
11. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. KJ Rhoden K Unger G Salvatore Y Yilmaz V Vovk G Chiappetta MB Qumsiyeh JL Rothstein A Fusco M Santoro H Zitzelsberger G Tallini, J Clin Endocrinol Metab 2006 91 2414 2423 10.1210/jc.2006-0240 16595592
12. Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. KJ Rhoden C Johnson G Brandao JG Howe BR Smith G Tallini, Lab Invest 2004 84 1557 1570 10.1038/labinvest.3700198 15502856
13. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. E Brzeziaska M Karbownik M Migdalska-Sk D Pastuszak-Lewandoska J Woch A Lewiski, Mutat Res 2006 599 26 35 16483615
14. ret/PTC-1 activation in Hashimoto thyroiditis. OM Sheils JJ O'Leary V Uhlmann K Lüttich EC Sweeney, J Surg Pathol 2000 8 185 189 10.1177/106689690000800305
15. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. A Wirtschafter R Schmidt D Rosen N Kundu M Santoro A Fusco H Multhaupt J Atkins MR Rosen W Keane JL Rothstein, Laryngoscope 1997 107 95 100 10.1097/00005537-199701000-00019 9001272
16. High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population. DY Kang KH Kim JM Kim SH Kim JY Kim HW Baik YS Kim, Thyroid 2007 11 1 7
17. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. MN Nikiforova CM Caudill P Biddinger YE Nikiforov, Int J Surg Pathol 2002 10 15 22 10.1177/106689690201000104 11927965
18. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. PM Sadow MC Heinrich CL Corless JA Fletcher V Nosé Endocr Pathol 2010 21 73 79 10.1007/s12022-009-9101-3 20012784